Ally Bridge joins Bain in $120M bet that speeding up manufacturing QC can hit big in post-pandemic world

Amber Tong

Senior Editor

The global tide of venture and private equity money flooding into biopharma — undeterred, if not boosted, by the public health crisis — is floating the boats of not just drug developers but also the vendors that help them do their job. In the latest example, China’s Ally Bridge Group and Switzerland’s Endeavour Vision have joined Bain Capital in contributing to Rapid Micro Biosystems’ $120 million financing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Ally Bridge joins Bain in $120M bet that speeding up manufacturing QC can hit big in post-pandemic world

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Al­ly Bridge joins Bain in $120M bet that speed­ing up man­u­fac­tur­ing QC can hit big in post-pan­dem­ic world

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Sen­a­tors want to know more on why No­vo is dis­con­tin­u­ing its in­sulin Lev­emir

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Ally Bridge joins Bain in $120M bet that speeding up manufacturing QC can hit big in post-pandemic world

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal